Glucotrack's 1-for-15 reverse split takes effect; its latest quarterly report shows $1.12m of cash and going-concern doubt

by Jonas Halvorsen · August 31, 2026

Companies Reporter, The MicroCap Herald

Before any of the arithmetic of Glucotrack, Inc.'s reverse stock split is worth reading, the condition of the balance sheet underneath it needs stating. In the quarterly report the company filed on August 14, 2026 covering the period ended June 30, 2026, Glucotrack disclosed that it held $1,124 thousand in cash and cash equivalents, down from $7,383 thousand at December 31, 2025, and included the standard formulation that these conditions raise substantial doubt about the company's ability to continue as a going concern. Those figures are two months old as of Monday and predate several financings the company has since described.

Against that backdrop, the share consolidation itself is straightforward. In an announcement dated August 27, 2026, Glucotrack said a 1-for-15 reverse stock split of its common stock would become effective at the opening of trading on Monday, August 31, 2026, with the shares beginning to trade on a split-adjusted basis the same day. The company said the ratio would reduce its outstanding common stock from 11,972,157 shares to approximately 798,144 shares. Stockholders who would otherwise be left with fractional shares will, in the release's own words, "automatically be entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share."

The mechanics were routine. Glucotrack said its stockholders approved the split at an annual meeting held August 18, 2026, that VStock Transfer, LLC is acting as exchange agent, and that the split-adjusted common stock carries a new CUSIP number, 45824Q887. The August 27 announcement contained no attributed statements from named company executives.

What the split is meant to fix

The stated purpose is listing compliance. Glucotrack said the consolidation is intended to raise the per-share trading price so the company can satisfy Nasdaq's requirement that a listed security maintain a minimum closing bid price of $1.00, and that the price must hold at or above that level through November 9, 2026. That framing sets the test rather than passing it: under Nasdaq's bid-price rules a company generally has to close at or above $1.00 for a defined run of consecutive business days before staff will confirm compliance, and a split that lifts the quoted price on day one says nothing about where it sits at the end of that run. It also does nothing to the company's market value: a reverse split divides the share count and multiplies the price by the same factor, and the product is unchanged.

The ownership change queued behind it

The more consequential item for existing holders is not the split but a transaction that closed six weeks earlier. In a release dated July 14, 2026, Glucotrack said it had completed a business combination with Lōkahi Therapeutics, which the announcement described as "a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets." Under the terms described in that release, Lōkahi securityholders are to receive approximately 90 percent of the combined company on a fully diluted basis following conversion of preferred stock, with pre-existing Glucotrack stockholders retaining approximately 10 percent.

That conversion has not happened. The July 14 release stated that the preferred stock is expected to convert into common equity "[u]pon receipt of required stockholder approvals and satisfaction of applicable Nasdaq listing requirements." The 90 percent figure therefore describes an outcome contingent on votes and listing clearance that the company has not announced as completed. Readers should hold the two share-count facts side by side: the split cuts the common share count to roughly 798,000, while the conversion described in July would, if approved, expand the fully diluted base far beyond it.

The combination also changed the executive suite. The July release said Erik Emerson had been appointed chief executive officer of the combined company, and that Paul Goode would serve as chief technical officer of the combined company and chief executive officer of the subsidiary housing Glucotrack's continuous blood glucose monitoring programme. Emerson said in the release that the transaction "establishes a capital-efficient, publicly listed platform designed to systematically identify, acquire, and advance differentiated healthcare assets." Goode said the combination "enables the continued advancement of Glucotrack's core technology within a focused operating structure while participating in a broader platform."

The numbers on record

Glucotrack's quarterly report for the period ended June 30, 2026 shows a GAAP net loss of $3,814 thousand for the three months, narrower than the $4,756 thousand reported for the same three months of 2025. For the six months the GAAP net loss was $8,148 thousand against $11,589 thousand a year earlier. Research and development spending was $4,148 thousand over the six months and general and administrative expense $3,455 thousand. Net cash used in operating activities was $7,664 thousand for the half. All of these are GAAP figures as presented in the filing; the company did not publish a reconciled non-GAAP measure alongside them.

The same filing lists subsequent events that bear directly on the cash position. It records the completion of the Lōkahi merger on July 14, 2026, a bridge financing of approximately $4,450 thousand in gross proceeds carried out at a 22 percent original issue discount, and an equity line of credit facility with a maximum purchase capacity of $50,000 thousand over three years. An original issue discount of that size means the company records materially more principal than it receives in cash, and an equity line is a mechanism for issuing shares over time rather than a committed cash balance. Neither is a substitute for the operating funding the going-concern language refers to.

One accounting point is worth flagging for anyone reconciling the share counts. The quarterly report gives 10,578,822 common shares outstanding as of its August 14 cover date, while the August 27 split announcement cites 11,972,157 shares immediately before the consolidation. The two figures are thirteen days apart and are not directly comparable; the company has not published a reconciliation between them, and this desk has not obtained one.

Glucotrack's securities trade on Nasdaq under the symbol GCTK. Monday's session was still in progress at the time of writing and no closing figure exists for the first day of split-adjusted trading.